

IDS Form PTO/SB/06: Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/524,738
				Filing Date	09/15/2005
				First Named Inventor	Steffen Goletz
				Art Unit	1642
				Examiner Name	Sean E. Aeder
Sheet	1	of	3	Attorney Docket Number	08358.0006-00000

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Initials	Cite No. ¹	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US-4,931,275	06-05-1990	Shinitzky et al.	
		US-5,948,646	09-07-1999	Srivastava	
		US-5,961,979	10-05-1999	Srivastava	
		US-6,168,793	01-02-2001	Srivastava	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁵
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				

NONPATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		Translation
		ALBERT, "Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs," <i>Nature</i> , 392:86-89 (1998).		
		ALLISON A. et al., "The role of cytokines in the action of immunological adjuvants," <i>Vaccine Design: The Role of Cytokine Networks</i> , Gregoriadis ed., NATO ASI Series A: Life Sciences, Vol. 293, pp.1-9, Plenum Press, NY (1997).		
		BERD, "Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases," <i>J. Clin. Oncol.</i> , 15:2359-2370 (1997).		
		BERTHIER-VERGNES, "Induction of IgG Antibodies Directed to a M, 31,000 Melanoma Antigen in Patients Immunized with Vaccinia Virus Melanoma Oncolysates," <i>Cancer Res.</i> 54:2433-2439 (1994).		
		BINDER, "Cutting Edge: Heat Shock Protein gp96 Induces Maturation and Migration of CD11c ⁺ Cells In Vivo," <i>J. Immunol.</i> , 165:6029-6035 (2000).		
		BOMFORD et al., "The control of the antibody isotype responses to recombinant human immunodeficiency virus gp120 antigen by adjuvants," <i>AIDS Res. Hum. Retroviruses</i> , 8:1765 et seq. (1992).		

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

2

of

3

Complete if Known

Application Number	10/524,738
Filing Date	09/15/2005
First Named Inventor	Steffen Goletz
Art Unit	1642
Examiner Name	Sean E. Aeder
Attorney Docket Number	08358.0006-00000

NONPATENT LITERATURE DOCUMENTS

BOURDON, "Inhibition of Tumoral Graft Growth by Pretreatment with Normal or Heat-modified Tumoral Cells," <i>Ann. Immunology</i> 1, 43-63 (1981).
CAO, "Immunodetection of epithelial mucin (MUC1, MUC3) and mucin-associated glycotopes (TF, Tn, and sialosyl-Tn) in benign and malignant lesions of colonic epithelium: apolar localization corresponds to malignant transformation," <i>Virchows Arch.</i> , 431:159-166 (1997).
CAVALIERE, "Selective heat sensitivity of cancer cells. Biochemical and clinical studies," <i>Cancer</i> 20:1351-1381 (1967).
CHECK, "Protection against transplanted and spontaneous lymphoma by inoculation of heat-altered syngeneic tumor cells in splenectomized mice," <i>Cancer</i> , 34:197-203 (1974).
CLAYMAN (ed.), <i>The American Medical Association Encyclopedia of Medicine</i> at 573-574, 576 and 1034 (1989).
COX et al., "Adjuvants -- A classification and review of their modes of action," <i>Vaccine</i> , Vol 15, pp 248 et seq., (1997).
COX et al., "Development of an Influenza-ISCOM.TM. Vaccine," in <i>Vaccine Design</i> at pp. 33-49 (1997).
CRYZ, Jr., S.J., <i>Immunotherapy and Vaccines</i> , edited by Stanley J. Cryz, pp. 3-11, VCH, Weinheim, Germany (1991).
DICKSON, "Hyperthermia in the treatment of cancer," <i>Lancet</i> , 1:202-205 (1979).
<i>Dictionary of Immunology</i> , pp. 3, 7, 46, 87-88, 94, 97, 105, 116.
DRESSEL, "Heat Shock Protein 70 Is Able to Prevent Heat Shock-Induced Resistance of Target Cells to CTL," <i>J. Immunol.</i> , 164:2362-2371 (2000).
FENG, "Stressed apoptotic tumor cells express heat shock proteins and elicit tumor-specific immunity," <i>Blood</i> , 97:3505-3512 (2001).
FERENCIK, M., <i>Handbook of Immunochemistry</i> , p. 115-116, Chapman & Hall (1993).
FUJIWARA, "Establishment of a tumor-specific immunotherapy model utilizing TNP-reactive helper T cell activity and its application to the autochthonous tumor system," <i>J. Immunol.</i> , 133:509-514 (1984).
<i>Fundamental Immunology</i> , p. 1007-1009, Ed. W.E. Paul, Raven Press, NY.
GALLUCI, "Danger signals: SOS to the immune system," <i>Curr. Opin. Immunol.</i> , 13:114-119 (2001).
GALLUCI, "Natural adjuvants: Endogenous activators of dendritic cells," <i>Nat. Med.</i> , 11:1249-1255 (1991).
GIOVANELLA, "Effects of Elevated Temperatures and Drugs on the Viability of L1210 Leukemia Cells," <i>Cancer Res.</i> , 30:1623-1631 (1970).
LUFTIG, R.B., <i>Microbiology and Immunology</i> , pp. 228-229, Lippincott-Raven Pub, Phila. (1998).
MACH, "Cytokine-secreting tumor cell vaccines," <i>Curr. Opin. Immunol.</i> 12, 571-575 (2000).
LEFFELL, Mary S., <i>An Overview of the Immune System: The Molecular Basis for Immune Responses</i> , in <i>Human Immunology Handbook</i> , pp. 1-45.
MELCHER, "Apoptosis or necrosis for tumor immunotherapy: what's in a name?" <i>J. Mol. Med.</i> 77:824-833 (1999).
MELCHER, "Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression," <i>Nat. Med.</i> , 4:581-587 (1998).
MISE, "Effect of Heat Treatment on Tumor Cells and Antitumor Effector Cells," <i>Cancer Res.</i> , 50:6199-6202 (1990).
MITCHELL, "Active Specific Immunotherapy for Melanoma: Phase I Trial of Allogeneic Lysates and a Novel Adjuvant," <i>Cancer Res.</i> , 48:5883-5893 (1988).

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	3	of	3
-------	---	----	---

Complete if Known

Application Number	10/524,738
Filing Date	09/15/2005
First Named Inventor	Steffen Goletz
Art Unit	1642
Examiner Name	Sean E. Aeder
Attorney Docket Number	08358.0006-00000

NONPATENT LITERATURE DOCUMENTS

	MONDOVI, "Increased immunogenicity of Ehrlich ascites cells after heat treatment," <i>Cancer</i> , (30):4:885-888 (1972).	
	PETERS et al., "Preparation of Immuno-Therapeutic Autologous Tumor Cell Vaccines from Solid Tumors," <i>Cancer Res.</i> , 39:1353-1360 (1979).	
	PHILLIPS, T., <i>Analytical Techniques in Immunochemistry</i> , pp. 307-310, Marcel Dekker, NY (1992).	
	PRICE, "Effect of heat and glutaraldehyde upon the immunogenicity of Meth A sarcoma cells," <i>Br. J. Cancer</i> 40:663-665 (1979).	
	RESTIFO, "Building better vaccines: how apoptotic cell death can induce inflammation and activate innate and adaptive immunity," <i>Curr. Opin. Immunol.</i> , 12:597-603 (2000).	
	ROMANI et al., "Proliferating dendritic cell progenitors in human blood," <i>J. Exp. Med.</i> , 180:83-93 (1994).	
	SCHILD, "gp96--the immune system's Swiss army knife," <i>Nat. Immunol.</i> 1:100-101 (2000).	
	SELAWRY, "Hyperthermia in Tissue-cultured Cells of Malignant Origin," <i>Cancer Res.</i> , 17:785-791 (1957).	
	SENSI, "Clonal Expansion of Lymphocytes in Human Metastases after Treatment With a Hapten-modified Autologous Tumor Vaccine," <i>Clin. Invest.</i> 99:710-717 (1997).	
	SHAIF-MUTHANA, "Dead or Alive: Immunogenicity of Human Melanoma Cells When Presented by Dendritic Cells," <i>Cancer Res.</i> , 60:6441-6447 (2000).	
	SIVANANDHAM, <i>Biological Therapy of Cancer</i> , Ed. Rosenberg, S.A., 632-647 (2000).	
	SNIPPE et al., "Adjuvant Directed Immune Specificity at the Epitope Level. Implications for Vaccine Development. A Model Study Using Semliki Forest Virus Infection of Mice," pp. 155-166 in <i>Vaccine Design</i> .	
	TODRYK, "Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake," <i>The Journal of Immunology</i> , 163:1398-1408 (1999).	
	VERMES, "A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V," <i>J. Immunol. Meth.</i> , 184:39-51 (1995).	
	WELLS, "Heat shock proteins, tumor immunogenicity and antigen presentation: an integrated view," <i>Immunol. Today</i> , 21:129-132 (2000).	